Login to Your Account



Search

Search results

Pharma: Clinic roundup

Merck & Co. Inc. , of Whitehouse Station, N.J., said the data monitoring committee for the Phase II/III EPOCH study testing MK-8931, an oral beta-amyloid precursor protein site-cleaving enzyme, or BACE, inhibitor, in mild to moderate Alzheimer’s ...

BioWorld Today - Staff - 2013-12-11 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Summit Corp. plc, of Oxford, UK, said the first Duchenne Muscular Dystrophy (DMD) patient has been enrolled and dosed in a Phase Ib clinical trial of the oral, small molecule utrophin modulator SMT C1100. (BioWorld-Today-2013-12-10) ...

BioWorld Today - Staff - 2013-12-10 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Shire plc , of London, reported top-line Phase III results with its lifitegrast dry-eye treatment. (BioWorld-Today-2013-12-09) ...

BioWorld Today - Staff - 2013-12-09 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Eli Lilly and Co., of Indianapolis, reported that three Phase III studies of edivoxetine failed to meet the primary objective of superior efficacy in major depressive disorder (MDD) after eight weeks of treatment. When added to a selective serotonin ...

BioWorld Today - Staff - 2013-12-06 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Sanofi SA , of Paris, reported full results from the EDITION II study of investigational insulin U300, showing that 23 percent fewer patients experienced night-time low blood sugar compared with Lantus (insulin glargine [rDNA origin] injection). ...

BioWorld Today - Staff - 2013-12-04 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Janssen Pharmaceutica NV , of Beerse, Belgium, part of Johnson & Johnson, reported results of the PALMFlexS study. Data showed flexible maintenance dosing with Xeplion (paliperidone palmitate) was associated with a clinically relevant treatme ...

BioWorld Today - Staff - 2013-12-03 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Pfizer Inc. , of New York, said it entered an agreement with Glaxosmithkline plc , of London, to explore the anticancer efficacy and safety of GSK’s trametinib (GSK1120212) combined with Pfizer’s palbociclib (PD-0332991) in a Phase I/II study ...

BioWorld Today - Staff - 2013-11-22 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• CSL Ltd. , of King of Prussia, Pa., presented data at the American Heart Association meeting in Dallas showing that CSL112 demonstrated favorable safety and tolerability when administered to patients with stable atherothrombotic disease and showed ...

BioWorld Today - Staff - 2013-11-21 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Boehringer Ingelheim GmbH , of Ingelheim, Germany, reported clinical results from a study of 145 healthy male volunteers showing that its fully humanized antibody fragment (Fab) rapidly reversed the anticoagulation effect of dabigatran, with onset ...

BioWorld Today - Staff - 2013-11-20 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Astrazeneca plc , of London, said it will conduct two new trials designed to build scientific understanding of Brilinta (ticagrelor) tablets in additional high-risk patient populations. One trial involves 9,600 patients who have experienced an acut ...

BioWorld Today - Staff - 2013-11-15 00:00 - 0 comments - 0 attachments